

# PERSISTENCE OF AN ANTIRETROVIRAL THERAPY IN HUMAN IMMUNODEFICIENCY VIRUS PATIENTS IN A TERTIARY LEVEL HOSPITAL

A. PINILLA RELLO<sup>1</sup>, H. NAVARRO AZNAREZ<sup>1</sup>, A. MAGALLÓN MARTÍNEZ<sup>1</sup>, B. ABAD BAÑUELOS<sup>1</sup>, Á. ARIAS SÁNCHEZ<sup>1</sup>, M.P. OLIER MARTÍNEZ<sup>1</sup>, A. GASSO SÁNCHEZ<sup>1</sup>, A. ESCOLANO PUEYO<sup>1</sup>, M.R. ABAD SAZATORNIL<sup>1</sup>.  
<sup>1</sup>UNIVERSITARY MIGUEL SERVET HOSPITAL, HOSPITAL PHARMACY, ZARAGOZA, SPAIN

## BACKGROUND

The guidelines of antiretroviral therapy (ART) for the Human Immunodeficiency Virus (HIV) recommend starting with all the patients, regardless of the levels of CD4 lymphocytes and the symptomatology.

## OBJETIVES

**Persistence:** time a patient stays with a treatment since the beginning until the interruption, regardless of the reason.

Aim of this research: comparison between the patients' persistence who different ART.

## METHODOLOGY

Descriptive, transversal and retrospective research that includes all the patients who have started an ART for HIV, 2013-10<sup>th</sup> October 2018, and who have suffered a change in the therapy.

Variables:

- Starting date and initial treatment
- Changing date and reason of the change.

Analysis: SPSS Statistics.

## RESULTS

Patients started with STRs: In 2013-2015, 20 (16,8%) and in 2016-2018, 31 (46,3%)

**616 patients have started ART and 186 (30,2%) of them have changed it**

	PATIENTS	ITIAN	THIRD DRUG	MEDIAN SURVIVAL*	MEDIAN SURVIVAL THIRD DRUG*
<b>STRs</b>	<b>51 (27,4%)</b>	40% (78,4%) TDF o TAF/FTC 11 (21,6%) ABC/3TC	32 (62,7%) INI 19 (37,3%) ITINN	229 days (IC95% 146,0-311,9)	103 days with INI (IC95%) 65,0-140,9)
<b>MTRs</b>	<b>135 (72,6%)</b>	115 (85,2%) TDF/FTC 16 (11,8%) ABC/3TC	72 (53,7%) IP 34 (25,4%) ITINN 28 (20,9%) INI	164 days (IC95% 87,8-240,2)	241 days with IP (IC95% 162,1-319,9) 265 days with ITINN (IC95% 162,1-367,9)

\*Only there are statistically significant differences between INI-IP and INI-ITINN median survival (p<0,05)

### Reasons for treatment change

48 (25,8%) simplification  
 19 (10,2%) virologic failure  
 7 (3,8%) interaction with home treatment  
 7 (3,8%) other causes

**105 (56,5%) toxicity.** Third drug:  
 - 39 (37,1%) IP  
 - 37 (35,2%) ITINN  
 - 29 (27,6%) INI

STRs: Single Tablet Regimens; MTRs: Multiple Tablet Regimens  
 ITIAN: Inverse Transcriptase Inhibitor Analogous Nucleosides  
 ITINN: Inhibitor Transcriptase Inverse No analogous Nucleosides

IP: Protease inhibitor  
 INI: Integrase inhibitor

## CONCLUSIONS

- ART combinations with **STRs** have a longer survival in the treatment and in patients **with ITINN** as a third drug, a greater survival is observed.
- The main cause of ART in naïve patients is **toxicity**.
- There is a **gradual use of STRs throughout the years studied**.

